CIK 0000920148 · Services-Medical Laboratories (SIC 8071) · NYSE · fiscal year ends 12/31
| FY2025 | FY2024 | FY2021 | FY2020 | |
|---|---|---|---|---|
| Revenue (USD) | 14.0 B | 11.9 B | ||
| Net income (USD) | 1.6 B | 883.7 M | ||
| Diluted EPS (USD/shares) | 10.46 | 13.97 |
| Filed | Form | Description | Period |
|---|---|---|---|
| 2026-10-21 | 8-K | 8-K items 7.01,9.01 | 2026-10-20 |
| 2026-09-30 | 8-K | 8-K items 7.01,9.01 | 2026-09-30 |
| 2026-09-22 | 8-K | 8-K items 7.01 | 2026-09-22 |
| 2026-09-10 | 8-K | 8-K items 7.01,9.01 | 2026-09-10 |
| 2026-09-03 | 4 | PRIMARY DOCUMENT | 2026-09-01 |
| 2026-09-03 | 4 | PRIMARY DOCUMENT | 2026-09-01 |
| 2026-09-03 | 4 | PRIMARY DOCUMENT | 2026-09-01 |
| 2026-09-03 | 4 | PRIMARY DOCUMENT | 2026-09-01 |
| 2026-08-28 | 8-K | 8-K items 7.01,9.01 | 2026-08-28 |
| 2026-08-18 | 4 | PRIMARY DOCUMENT | 2026-08-17 |
| 2026-08-17 | 144 | 144 | |
| 2026-08-17 | 8-K | 8-K items 7.01,9.01 | 2026-08-17 |
| 2026-08-14 | 8-K | 8-K items 5.02 | 2026-08-11 |
| 2026-08-12 | 4 | PRIMARY DOCUMENT | 2026-08-11 |
| 2026-08-11 | 144 | 144 | |
| 2026-08-06 | 4 | PRIMARY DOCUMENT | 2026-08-04 |
| 2026-08-05 | 10-Q | 10-Q | 2026-06-30 |
| 2026-08-05 | 4 | PRIMARY DOCUMENT | 2026-08-03 |
| 2026-08-04 | 144 | 144 | |
| 2026-07-30 | 8-K | 8-K items 2.02,9.01 | 2026-07-30 |
| 2026-07-10 | 8-K | 8-K items 7.01,9.01 | 2026-07-08 |
| 2026-07-06 | 4 | PRIMARY DOCUMENT | 2026-07-01 |
| 2026-07-06 | 4 | PRIMARY DOCUMENT | 2026-07-01 |
| 2026-07-02 | 144 | 144 | |
| 2026-07-02 | 144 | 144 |
Forms on file (last 1,000): 4 594, 8-K 191, 144 63, 10-Q 23, 3 22, S-8 POS 18, SC 13G/A 17, DEFA14A 9. Source: SEC EDGAR, as filed; this page is public data and not investment advice.
GET https://store.agentexchange.work/gw/filings/company?ticker=LH (0.002 USD), /gw/filings/filings?ticker=LH&form=8-K, /gw/filings/facts?ticker=LH&concept=Revenues, full-text /gw/filings/search?q=.... Pay per call in USDC (x402) or with a 19 USD card key for 1,000 calls. Catalogue · llms.txtUpdated from EDGAR within 30 minutes of a filing. Agent Exchange